BOMSS Patient Safety Committee Alert on the use of Gliflozins
« View all News items
10
Mar
2022
Dear Fellows and Members,
We would like to draw your attention to this patient safety alert issued by the British Obesity and Metabolic Surgery Society (BOMSS).
https://bomss.org/wp-content/uploads/2022/03/BOMSS-PSA-SGLT-2i.pdf
Though this alert is specific to patients pre or post bariatric surgery, the issue of ketoacidosis with serum glucose co-transporter-2 inhibitors (SGLT-2i), loosely known as gliflozins, is relevant to each one of us because all patients undergoing major surgery and those presenting with acute serious illnesses are at risk.
This is all the more important because these drugs are being increasingly used in the management of Type 2 Diabetes Mellitus.
Best wishes,
Patient Safety Group at Royal College of Surgeons of Edinburgh
